{"page":{"totalFilteredElements":90},"studies":[{"active":true,"description":"Klinische Forschungsplattform zur \nErfassung der Entscheidungsfindung in der Biomarker-basierten \nPr&#228;zisionsonkologie und deren klinische Bedeutung","eudractNumber":null,"id":5702,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04389541","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2020-07-13T08:22:15+02:00","shortTitle":"INFINITY","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Nicht-interventionelle Beobachtungsstudie zur Bewertung der Lebensqualit&#228;t (HRQoL) bei Patienten mit rezidiviertem und/oder refrakt&#228;rem Multiplen Myelom, die eine vorherige Therapielinie erhalten haben und mit Isatuximab behandelt werden.","eudractNumber":null,"id":11929,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-03-12T08:47:20+01:00","shortTitle":"IsaPRO","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Jade - Klinische Forschungsplattform zur Behandlung und zum Ergebnis bei Patienten mit hepatozellul&#228;rem oder cholangiozellul&#228;rem Krebs<br />","eudractNumber":null,"id":6544,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04510740","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2020-08-31T12:11:49+02:00","shortTitle":"JADE - Registerplattform Leberkrebs","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Analyse des Gesamt- und Tumorfreien &#220;berlebens von Patienten mit Kolonkarzinomen als indirekter Parameter der Chemotherapie-Effektivit&#228;t einer definierten Chemotherapie in Abh&#228;ngigkeit von der anatomischen Lokalisation des Prim&#228;rtumors im adjuvanten Ansatz.","eudractNumber":null,"id":8311,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2014-06-01T08:18:06+02:00","shortTitle":"Kolonsegment(Chemo)-Studie","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Liquid Biopsy als Biomarker unter PSMA-Radioligandentherapie","eudractNumber":null,"id":11461,"indications":[{"id":"pro","name":"Prostatakrebs"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT07118436","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-05-01T09:40:08+02:00","shortTitle":"LOOPS","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prospektive NIS zu klinischen Outcomes bei Patienten mit fortgeschrittenem nicht kleinzelligem Lungenkrebs (NSCLC) mit EGFR Mutation unter Behandlung mit zugelassenem Amivantamab-haltigen Therapieschemata im Rahmen der standardm&#228;&#223;igen klinischen Praxis","eudractNumber":null,"id":11841,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-01-12T11:41:58+01:00","shortTitle":"Lepidoptera","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<div>Constructing and validation of a robust, affordable, and widely applicable real-world outcome predictor for risk-tailored therapy for DLBCL patients in the German healthcare system</div>","eudractNumber":null,"id":11186,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06526065","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-02-13T09:32:25+01:00","shortTitle":"MMML-Predict","therapeutical":false,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Ohrakupressur bei Patienten mit Multiplem Myelom - eine randomisierte kontrollierte Studie","eudractNumber":null,"id":8932,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05762250","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-08-17T11:04:30+02:00","shortTitle":"MY_ACU","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"International, multicenter, non-interventional PASS study&#160; to evaluatemthe effectiveness and safety of elranatamab in patients with relapsed/refractory multiple myelom treated in real world settings","eudractNumber":null,"id":11259,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-08-01T11:47:23+02:00","shortTitle":"MagnetisMM-16","therapeutical":false,"therapyLines":[]},{"active":true,"description":"MYRIAM: Clinical Research platform for molecular testing, treatment and outcome of patients with Multiple Myeloma (Myeloma Registry Platform: MYRIAM)","eudractNumber":null,"id":4528,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT03308474","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2018-01-18T12:17:40+01:00","shortTitle":"Myeloma Registry Platform (MYRIAM)","therapeutical":false,"therapyLines":[]}]}